Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleVemurafenib.AuthorsFlaherty, Keith. T; Yasothan, Uma; Kirkpatrick, PeterAbstractIn August 2011 vemurafenib (Zelboraf; Daiichi Sankyo/Roche), an inhibitor of BRAF kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma with the BRAF(V600E) mutation.SubjectsUNITED States; MELANOMA treatment; UNITED States. Food &; Drug Administration; FOCAL adhesion kinase; EFFECT of drugs on T cellsPublicationNature Reviews Drug Discovery, 2011, Vol 10, Issue 11, p811ISSN1474-1776Publication typejournal articleDOI10.1038/nrd3579